Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 9/20 | 0.58 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.52 |
| ▸ | RXRA | P19793 | 1/20 | 0.52 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | PPARA | Q07869 | 6/20 | 0.42 |
| ▸ | ITGB3 | P05106 | 5/20 | 0.40 |
| ▸ | ITGAV | P06756 | 5/20 | 0.40 |
| ▸ | ITGB1 | P05556 | 4/20 | 0.40 |
| ▸ | ITGA5 | P08648 | 4/20 | 0.40 |
| ▸ | PPARD | Q03181 | 3/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13743033 | 0.91 | PPARG (0.53) | PPARGCYP3A4RXRALMNAL3MBTL1 | |
| SCHEMBL20110590 | 0.88 | PPARG (0.52) | PPARGCYP3A4RXRALMNAL3MBTL1 | |
| SCHEMBL1201518 | 0.88 | PPARG (0.54) | PPARGCYP3A4RXRALMNAL3MBTL1 | |
| SCHEMBL4874828 | 0.86 | PPARG (0.58) | PPARGCYP3A4RXRALMNAL3MBTL1 | |
| Hydrochloric Acid SCHEMBL5738405 | 0.85 | PPARG (0.57) | PPARGCYP3A4RXRALMNAL3MBTL1 | |
| SCHEMBL2332479 | 0.84 | PPARA (0.61) | PPARGPPARAPPARD | |
| SCHEMBL2361274 | 0.84 | PPARA (0.61) | PPARGPPARAPPARD | |
| SCHEMBL2332774 | 0.84 | PPARA (0.61) | PPARGPPARAPPARD | |
| SCHEMBL13475126 | 0.84 | PPARG (0.69) | PPARGCYP3A4RXRAPPARAITGB3 | |
| SCHEMBL1201520 | 0.83 | PPARG (0.51) | PPARGCYP3A4RXRALMNAL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2010084638-A1 | METHOD FOR INHIBITING DEHYDROBROMINATION OF METHYL 2-BROMO-3-[4-[2-(5-ETHYL-2-PYRIDYL)ETHOXY]PHENYL]PROPIONATE | 株式会社トクヤマ (JP) | 2010-07-29 | — | — | WO | disclosed |
| WO-2010084638-A1 | METHOD FOR INHIBITING DEHYDROBROMINATION OF METHYL 2-BROMO-3-[4-[2-(5-ETHYL-2-PYRIDYL)ETHOXY]PHENYL]PROPIONATE | 株式会社トクヤマ (JP) | 2010-07-29 | — | — | WO | disclosed |
| JP-2010126528-A | METHOD FOR PRODUCING METHYL 2-BROMO-3-{4-[2-(5-ETHYL-2-PYRIDYL)ETHOXY]PHENYL}PROPIONATE | TOKUYAMA CORP | 2010-06-10 | — | — | JP | disclosed |
| WO-2010041538-A1 | PROCESS FOR PRODUCING CARBONYLOXY COMPOUND | 株式会社トクヤマ (JP) | 2010-04-15 | — | — | WO | disclosed |
| EP-1623977-B1 | INTERMEDIATE COMPOUND WHICH IS USED FOR THE PREPARATION OF PIOGLITAZONE | MEDICHEM SA (ES) | 2007-11-07 | — | — | EP | disclosed |
| EP-1387843-B1 | METHOD FOR OBTAINING PIOGLITAZONE AS AN ANTIDIABETIC AGENT | ZENTIVA AS (CZ) | 2007-02-28 | — | — | EP | disclosed |
| US-7009057-B2 | Method for obtaining pioglitazone as an antidiabetic agent | ZENTIVA A.S. (CZ) | 2006-03-07 | — | — | US | disclosed |
| EP-1622898-A1 | PROCESSES FOR MAKING THIAZOLIDINEDIONE DERIVATIVES AND COMPOUNDS THEREOF | Synthon B.V. (NL) | 2006-02-08 | — | — | EP | disclosed |
| US-20050059708-A1 | Processes for making thiazolidinedione derivatives and compounds thereof | SYNTHON BV (NL) | 2005-03-17 | — | — | US | disclosed |
| US-20050043360-A1 | Method for obtaining pioglitazone as an antidiabetic agent | LECIVA, A.S. (CZ) | 2005-02-24 | — | — | US | disclosed |
| WO-2004101560-A1 | PROCESSES FOR MAKING THIAZOLIDINEDIONE DERIVATIVES AND COMPOUNDS THEREOF | SYNTHON B.V. (NL) | 2004-11-25 | — | — | WO | disclosed |
| EP-1387843-A1 | METHOD FOR OBTAINING PIOGLITAZONE AS AN ANTIDIABETIC AGENT | Leciva, A.S. (CZ) | 2004-02-11 | — | — | EP | disclosed |
| WO-2002088120-A1 | METHOD FOR OBTAINING PIOGLITAZONE AS AN ANTIDIABETIC AGENT | Léciva, a.s. (CZ) | 2002-11-07 | — | — | WO | disclosed |
| EP-0193256-B1 | THIAZOLIDINEDIONE DERIVATIVES, THEIR PRODUCTION AND USE | Takeda Chemical Industries, Ltd. (JP) | 1989-04-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050059708-A1 | Processes for making thiazolidinedione derivatives and compounds thereof | PPARD, PPARG, PPARA | PPARG 2/4885CYP3A4 28/4885RXRA 265/4885 |
| US-20050043360-A1 | Method for obtaining pioglitazone as an antidiabetic agent | GLP1R, INSR, CBR3 | PPARG 6/4885CYP3A4 221/4885RXRA 61/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.